Trials / Unknown
UnknownNCT02805010
Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously
A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Dose of Abatacept 125mg Administered Subcutaneously in Chinese Healthy Subjects
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objective of the study is to assess the single dose PK, safety, tolerability and immunogenicity of abatacept 125mg administered SC in Chinese healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abatacept | On Day 1, subjects will receive a single SC dose of abatacept 125mg |
| OTHER | Placebo | On Day 1, subjects will receive a single SC dose of placebo |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2017-02-01
- Completion
- 2017-02-01
- First posted
- 2016-06-17
- Last updated
- 2016-12-06
Source: ClinicalTrials.gov record NCT02805010. Inclusion in this directory is not an endorsement.